Similarly, a wide literature, recently synthesized by Wongso et al. [45], already reported a potential for TSPO-targeting radioligands for both diagnosis and treatment of various types of cancers, including colorectal, brain, breast, prostate, and lung cancers, as well as melanoma. Here, TSPO is linked to melanoma.